1st patient dosed in trial of PRMT5 inhibitor for glioblastoma
The first participant has been dosed in a Phase 1/2 trial investigating TNG456, a PRMT5 inhibitor to treat people with advanced solid tumors with MTAP…
Glioma
BCB-276 cell therapy for pediatric brain cancer gets new FDA status
BCB-276, an experimental cell therapy that Brainchild Bio is developing for diffuse intrinsic pontine glioma (DIPG), has been named a regenerative medicine advanced…
New partners to help develop CAR T-cell therapy for brain cancer
Optieum Biotechnologies and Genezen are teaming up to help develop OPTF01, an experimental cell therapy for glioblastoma, an aggressive form of glioma.
Viralgen, Trogenix collaborate on glioblastoma treatment
Contract development and manufacturing organization Viralgen said it has scaled up production of Trogenix’s glioblastoma treatment TGX-007, as the companies move the gene therapy…
Supporters to #GoGrayinMay for Brain Tumor Awareness Month
Each May marks Brain Tumor Awareness Month, with annual efforts to raise awareness about glioma and other types of cancer that affect the brain.
BCB-276 for DIPG brain cancer named FDA breakthrough therapy
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to the cell therapy BCB-276 as a potential treatment for diffuse intrinsic…
Proteins could be biomarkers for glioma-related epilepsy: Study
The LY6H and GRM3 proteins could serve as potential biomarkers of glioma-related epilepsy (GRE), according to a study. Among people with gliomas, both proteins…
Personalized Mekinist dosing may be needed for kids with glioma
Personalized dosing and monitoring of drug levels may be necessary for children with low-grade glioma treated with Mekinist (trametinib), according to a study. The…
CAN-2409 combo therapy shows survival benefits in brain cancer
CAN-2409 (aglatimagene besadenovec), Candel Therapeutics‘ investigational immunotherapy, was safe and demonstrated potential survival benefits in patients with high-grade glioma, an aggressive type of…
Glioblastoma trial of VXM01 plus Bavencio shows promising safety
Combining VXM01, an experimental anticancer vaccine, with Bavencio (avelumab), which activates the immune system to attack cancer cells, was well tolerated in a…
